SG11201901548SA - Anti-tim-3 antibodies and use thereof - Google Patents
Anti-tim-3 antibodies and use thereofInfo
- Publication number
- SG11201901548SA SG11201901548SA SG11201901548SA SG11201901548SA SG11201901548SA SG 11201901548S A SG11201901548S A SG 11201901548SA SG 11201901548S A SG11201901548S A SG 11201901548SA SG 11201901548S A SG11201901548S A SG 11201901548SA SG 11201901548S A SG11201901548S A SG 11201901548SA
- Authority
- SG
- Singapore
- Prior art keywords
- science park
- beijing
- changping
- international
- tim
- Prior art date
Links
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 abstract 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 abstract 2
- 102220240796 rs553605556 Human genes 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000006870 function Effects 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
1 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 March 2018 (01.03.2018) W I PO I PCT 0111111010 0111 °nolo III 011101110111 O II oimIE (10) International Publication Number WO 2018/036561 Al (51) International Patent Classification: CO7K 16/28 (2006.01) A61P 35/00 (2006.01) A61K 39/395 (2006.01) A61P 37/00 (2006.01) (21) International Application Number: PCT/CN2017/099098 (22) International Filing Date: 25 August 2017 (25.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PCT/CN2016/096924 26 August 2016 (26.08.2016) CN (71) Applicant: BEIGENE, LTD.; c/o Mourant Ozannes Cor- porate Services (Cayman) Limited, 94 Solaris Avenue, Ca- mana Bay, Grand Cayman KY1-1108 (KY). (72) Inventor; and (71) Applicant (for SC only): ZHANG, Tong [CN/CN]; No.30 Science Park Road, Zhongguancun Life Science Park, Changping, Beijing 102206 (CN). (72) Inventors: XUE, Liu; No.30 Science Park Road, Zhong- guancun Life Science Park, Changping, Beijing 102206 (CN). LIU, Qi; No.30 Science Park Road, Zhongguan- cun Life Science Park, Changping, Beijing 102206 (CN). PENG, Hao; No.30 Science Park Road, Zhongguancun Life Science Park, Changping, Beijing 102206 (CN). WEI, Min; No.30 Science Park Road, Zhongguancun Life Science Park, Changping, Beijing 102206 (CN). LI, Kang; No.30 Science Park Road, Zhongguancun Life Science Park, Changping, Beijing 102206 (CN). TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) = (74) Agent: WU, FENG & ZHANG CO.; Room 305, Tower B, Beijing Aerospace Cpmiec Building, Beijing 100080 (CN). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (54) Title: ANTI-TIM-3 ANTIBODIES AND USE THEREOF 0 (57) : Provided are antibodies that specifically bind to T-cell immunoglobulin domain and mucin domain 3 (Tim-3). The \" anti-Tim-3 antibodies can be used to treat, prevent or diagnose immune, cancerous, infectious diseases or other pathological disorders 0 that may be modulated by Tim-3-mediated functions.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016096924 | 2016-08-26 | ||
| PCT/CN2017/099098 WO2018036561A1 (en) | 2016-08-26 | 2017-08-25 | Anti-tim-3 antibodies and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901548SA true SG11201901548SA (en) | 2019-03-28 |
Family
ID=61246369
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901548SA SG11201901548SA (en) | 2016-08-26 | 2017-08-25 | Anti-tim-3 antibodies and use thereof |
| SG10201912199XA SG10201912199XA (en) | 2016-08-26 | 2017-08-25 | Anti-tim-3 antibodies and use thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912199XA SG10201912199XA (en) | 2016-08-26 | 2017-08-25 | Anti-tim-3 antibodies and use thereof |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11203637B2 (en) |
| EP (2) | EP3970749A1 (en) |
| JP (2) | JP6968872B2 (en) |
| KR (1) | KR102460525B1 (en) |
| CN (3) | CN109790218B (en) |
| AU (1) | AU2017317227B2 (en) |
| BR (1) | BR112019003976A2 (en) |
| CA (1) | CA3034962A1 (en) |
| EA (1) | EA201990594A1 (en) |
| IL (1) | IL264970B2 (en) |
| MX (1) | MX2019002242A (en) |
| NZ (1) | NZ751246A (en) |
| SG (2) | SG11201901548SA (en) |
| TW (2) | TWI850696B (en) |
| WO (1) | WO2018036561A1 (en) |
| ZA (1) | ZA201901113B (en) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3044234T3 (en) * | 2013-09-13 | 2020-05-18 | Beigene Switzerland Gmbh | Anti-PD1 antibodies and their use as therapeutics and diagnostics |
| KR102130600B1 (en) | 2014-07-03 | 2020-07-08 | 베이진 엘티디 | Anti-PD-L1 Antibodies and Their Use as Therapeutics and Diagnostics |
| NZ749997A (en) | 2016-07-05 | 2022-11-25 | Beigene Ltd | Combination of a pd-l antagonist and a raf inhibitor for treating cancer |
| US20190248893A1 (en) | 2016-07-14 | 2019-08-15 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
| EP4353747A3 (en) | 2016-08-19 | 2024-06-26 | BeiGene Switzerland GmbH | Combination of zanubrutinib with an anti-cd20 or an anti-pd-1 antibody for use in treating cancer |
| TWI850696B (en) | 2016-08-26 | 2024-08-01 | 英屬開曼群島商百濟神州有限公司 | Anti-tim-3 antibodies and use thereof |
| MA46113A (en) | 2016-11-01 | 2019-07-10 | Anaptysbio Inc | ANTIBODIES DIRECTED AGAINST T-LYMPHOCYTE IMMUNOGLOBULIN AND MUCINE PROTEIN 3 (TIM-3) |
| CA3049536A1 (en) | 2017-01-09 | 2018-07-12 | Tesaro, Inc. | Methods of treating cancer with anti-tim-3 antibodies |
| CA3066518A1 (en) | 2017-06-26 | 2019-01-03 | Beigene, Ltd. | Immunotherapy for hepatocellular carcinoma |
| KR102776166B1 (en) | 2017-08-07 | 2025-03-04 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | Platform for generating safe cell therapeutics |
| US11786529B2 (en) | 2017-11-29 | 2023-10-17 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors |
| US12202894B2 (en) | 2018-03-20 | 2025-01-21 | WuXi Biologics Ireland Limited | Anti-TIM-3 antibodies |
| WO2019183551A1 (en) | 2018-03-23 | 2019-09-26 | Bristol-Myers Squibb Company | Antibodies against mica and/or micb and uses thereof |
| CN116789827A (en) * | 2018-04-12 | 2023-09-22 | 南京维立志博生物科技有限公司 | Methods of treating diseases using TIM-3 binding antibodies |
| WO2019223733A1 (en) | 2018-05-23 | 2019-11-28 | Beigene, Ltd. | Anti-ox40 antibodies and methods of use |
| CN112512582B (en) * | 2018-08-20 | 2024-04-16 | 江苏恒瑞医药股份有限公司 | Application of TIM-3 antibody in preparation of medicines for treating tumors |
| CN118667020A (en) * | 2018-08-21 | 2024-09-20 | 阿尔伯特爱因斯坦医学院 | Monoclonal antibodies against human TIM-3 |
| CN114174538A (en) | 2019-05-30 | 2022-03-11 | 百时美施贵宝公司 | Multiple tumor gene signatures suitable for immunooncology therapy |
| EP3977132A1 (en) | 2019-05-30 | 2022-04-06 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
| WO2020243568A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
| JP2022537411A (en) * | 2019-06-21 | 2022-08-25 | シングル セル テクノロジー， インコーポレイテッド | Anti-TIM-3 antibody |
| CN110498855A (en) * | 2019-07-25 | 2019-11-26 | 钟小泉 | A kind of TIM-3 antibody and application thereof |
| EP4061845A4 (en) * | 2019-11-21 | 2023-12-13 | BeiGene, Ltd. | Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tim3 antibodies |
| CN111995681B (en) * | 2020-05-09 | 2022-03-08 | 华博生物医药技术（上海）有限公司 | anti-TIGIT antibody, preparation method and application thereof |
| TW202216768A (en) | 2020-06-22 | 2022-05-01 | 美商恩格姆生物製藥公司 | Lair-1-binding agents and methods of use thereof |
| CN116438199A (en) | 2020-08-31 | 2023-07-14 | 百时美施贵宝公司 | Cell localization features and immunotherapy |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| ES3023507T3 (en) | 2020-12-28 | 2025-06-02 | Bristol Myers Squibb Co | Antibody compositions and methods of use thereof |
| EP4267172A1 (en) | 2020-12-28 | 2023-11-01 | Bristol-Myers Squibb Company | Subcutaneous administration of pd1/pd-l1 antibodies |
| CN112679613B (en) * | 2021-03-12 | 2021-10-01 | 广东新征程生命科学有限公司 | Application of bone marrow mesenchymal stem cells in combination with monoclonal antibody in treatment of cancer |
| US20240376224A1 (en) | 2021-04-02 | 2024-11-14 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| CN117377692A (en) | 2021-04-23 | 2024-01-09 | 苏州逻晟生物医药有限公司 | TIM-3-targeting antibodies and uses thereof |
| US20250206775A1 (en) | 2022-03-18 | 2025-06-26 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
| KR20250022071A (en) | 2022-06-02 | 2025-02-14 | 브리스톨-마이어스 스큅 컴퍼니 | Antibody composition and method of use thereof |
| WO2024041651A1 (en) * | 2022-08-25 | 2024-02-29 | Beigene, Ltd. | Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies and anti-lag3 antibodies |
| WO2024044675A1 (en) | 2022-08-25 | 2024-02-29 | Beigene, Ltd. | Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies |
| WO2024041652A1 (en) * | 2022-08-25 | 2024-02-29 | Beigene, Ltd. | Methods of cancer treatment |
| WO2024184810A1 (en) | 2023-03-06 | 2024-09-12 | Beigene Switzerland Gmbh | Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use |
| TW202436345A (en) | 2023-03-06 | 2024-09-16 | 瑞士商百濟神州瑞士有限責任公司 | Anti-cd3 multispecific antibodies and methods of use |
| WO2024184812A1 (en) | 2023-03-06 | 2024-09-12 | Beigene Switzerland Gmbh | Anti-cldn6 antibodies and methods of use |
| CN117777306B (en) * | 2023-07-04 | 2024-08-20 | 深圳豪石生物科技有限公司 | Enhanced chimeric antigen receptor targeting CLDN18.2 and application thereof |
| WO2025038763A1 (en) | 2023-08-15 | 2025-02-20 | Bristol-Myers Squibb Company | Ceramic hydroxyapatite chromatography flow through method |
| CN117777307B (en) * | 2023-09-26 | 2024-08-20 | 深圳豪石生物科技有限公司 | CLDN18.2 specific chimeric T cell receptor, chimeric T cell receptor immune cell and application thereof |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US7563874B2 (en) | 1998-08-31 | 2009-07-21 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| MXPA04000034A (en) * | 2001-06-29 | 2005-11-23 | Univ Leland Stanford Junior | T cell regulatory genes and methods of use thereof. |
| WO2003063792A2 (en) | 2002-01-30 | 2003-08-07 | The Brigham And Women's Hospital, Inc. | Compositions and methods related to tim-3, a th1-specific cell surface molecule |
| CA2703947C (en) | 2007-10-26 | 2018-12-04 | Governing Council Of The University Of Toronto | Therapeutic and diagnostic methods using tim-3 |
| WO2009155609A1 (en) | 2008-06-20 | 2009-12-23 | Oklahoma Medical Research Foundation | IMMUNOGENIC MEMAPSIN 2 β-SECRETASE PEPTIDES AND METHODS OF USE |
| HUE040213T2 (en) | 2010-06-11 | 2019-02-28 | Kyowa Hakko Kirin Co Ltd | Anti-tim-3 antibody |
| US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
| CN102492038B (en) * | 2011-12-09 | 2014-05-28 | 中国人民解放军军事医学科学院基础医学研究所 | Anti-human Tim-3 neutralized monoclonal antibody L3D and application thereof |
| EP3038634A4 (en) * | 2013-08-28 | 2017-10-11 | AbbVie Stemcentrx LLC | Novel sez6 modulators and methods of use |
| DK3044234T3 (en) | 2013-09-13 | 2020-05-18 | Beigene Switzerland Gmbh | Anti-PD1 antibodies and their use as therapeutics and diagnostics |
| CN103721255A (en) | 2014-01-07 | 2014-04-16 | 苏州大学 | Application of co-blocking of PD-1 and TIM-3 signal paths to anti-stomach-cancer treatment |
| JOP20200096A1 (en) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | Antibody molecules to tim-3 and uses thereof |
| KR102130600B1 (en) * | 2014-07-03 | 2020-07-08 | 베이진 엘티디 | Anti-PD-L1 Antibodies and Their Use as Therapeutics and Diagnostics |
| CN110294807B (en) * | 2014-10-27 | 2023-05-12 | 新加坡科技研究局 | anti-TIM-3 antibody |
| CN107001475B (en) | 2014-11-06 | 2021-01-29 | 豪夫迈·罗氏有限公司 | anti-TIM 3 antibodies and methods of use |
| TWI850696B (en) | 2016-08-26 | 2024-08-01 | 英屬開曼群島商百濟神州有限公司 | Anti-tim-3 antibodies and use thereof |
-
2017
- 2017-08-25 TW TW111125696A patent/TWI850696B/en active
- 2017-08-25 WO PCT/CN2017/099098 patent/WO2018036561A1/en unknown
- 2017-08-25 CA CA3034962A patent/CA3034962A1/en active Pending
- 2017-08-25 EP EP21190971.8A patent/EP3970749A1/en active Pending
- 2017-08-25 AU AU2017317227A patent/AU2017317227B2/en active Active
- 2017-08-25 IL IL264970A patent/IL264970B2/en unknown
- 2017-08-25 CN CN201780052246.5A patent/CN109790218B/en active Active
- 2017-08-25 SG SG11201901548SA patent/SG11201901548SA/en unknown
- 2017-08-25 NZ NZ751246A patent/NZ751246A/en unknown
- 2017-08-25 CN CN202310121523.0A patent/CN116655790A/en active Pending
- 2017-08-25 EP EP17842983.3A patent/EP3504243B1/en not_active Withdrawn - After Issue
- 2017-08-25 JP JP2019511565A patent/JP6968872B2/en active Active
- 2017-08-25 SG SG10201912199XA patent/SG10201912199XA/en unknown
- 2017-08-25 MX MX2019002242A patent/MX2019002242A/en unknown
- 2017-08-25 TW TW106129066A patent/TWI769174B/en active
- 2017-08-25 CN CN202310121525.XA patent/CN116478290A/en active Pending
- 2017-08-25 EA EA201990594A patent/EA201990594A1/en unknown
- 2017-08-25 BR BR112019003976A patent/BR112019003976A2/en unknown
- 2017-08-25 KR KR1020197007868A patent/KR102460525B1/en active Active
- 2017-08-25 US US16/328,047 patent/US11203637B2/en active Active
-
2019
- 2019-02-21 ZA ZA2019/01113A patent/ZA201901113B/en unknown
-
2021
- 2021-10-27 JP JP2021175867A patent/JP7158552B2/en active Active
- 2021-11-15 US US17/526,817 patent/US20220135675A1/en not_active Abandoned
-
2023
- 2023-09-27 US US18/475,552 patent/US20240076375A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901548SA (en) | Anti-tim-3 antibodies and use thereof | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201901716TA (en) | Adenovirus armed with bispecific t cell engager (bite) | |
| SG11201805451TA (en) | Immune effector cell therapies with enhanced efficacy | |
| SG11201805137XA (en) | Virus encoding an anti-tcr-complex antibody or fragment | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201909022PA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201900745VA (en) | Substituted thiazolo-pyridine compounds as malt1 inhibitors | |
| SG11201901834WA (en) | Micrornas as biomarkers for endometriosis | |
| SG11201901351UA (en) | A patient interface, system and method | |
| SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
| SG11201906958TA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
| SG11201906959RA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
| SG11201901347UA (en) | Compositions and methods for cancer immunotherapy | |
| SG11201810801QA (en) | Brain delivery protein | |
| SG11201803692PA (en) | Anti-5t4 antibodies and antibody-drug conjugates | |
| SG11201804597TA (en) | Vaccination with mica/b alpha 3 domain for the treatment of cancer | |
| SG11201910195WA (en) | Methods for trapping and barcoding discrete biological units in hydrogel | |
| SG11201808829VA (en) | Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease | |
| SG11201807255YA (en) | Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201908275XA (en) | Peptides and methods for the treatment of diabetes |